{
    "clinical_study": {
        "@rank": "60373", 
        "arm_group": {
            "arm_group_label": "Natalizumab", 
            "arm_group_type": "Experimental", 
            "description": "300 mg of Natalizumab intravenously (IV) every 4 weeks"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to determine the pharmacokinetic profile of multiple\n      doses of natalizumab in pediatric subjects with relapsing-remitting multiple sclerosis\n      (RRMS). The secondary objectives are as follows: to characterize the PD profile of\n      natalizumab (as defined by \u03b14 integrin binding) and to explore the safety and tolerability\n      of multiple doses of natalizumab in the pediatric population."
        }, 
        "brief_title": "PK and PD Study of Natalizumab in Pediatric Subjects With RRMS", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsing-Remitting Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Rapidly evolving severe relapsing remitting multiple sclerosis, defined by 2 or more\n             disabling relapses in 1 year, and with 1 or more gadolinium-enhancing lesions on\n             brain MRI or a significant increase in T2 lesion load, as compared to a previous\n             recent magnetic resonance imaging  (MRI)\n\n          -  Other inclusion criteria may apply\n\n        Exclusion Criteria:\n\n          -  History of, or abnormal laboratory values indicative of, significant medical,\n             neurologic (other than MS), or psychiatric disorders that might preclude\n             participation in the study in the opinion of the Investigator.\n\n          -  Prior natalizumab therapy.\n\n          -  Other exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884935", 
            "org_study_id": "101MS328", 
            "secondary_id": "2012-005082-13"
        }, 
        "intervention": {
            "arm_group_label": "Natalizumab", 
            "description": "300mg Intravenous administration every 4 weeks", 
            "intervention_name": "Natalizumab", 
            "intervention_type": "Biological", 
            "other_name": "Tysabri"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Pediatric", 
        "lastchanged_date": "November 1, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cefalu", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gallarate", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padua", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RMS)", 
        "overall_contact": {
            "email": "neurologyclinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: National Institute of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "predose (trough) concentrations from multiple dosing (Cpredose)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 16"
            }, 
            {
                "measure": "maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }, 
            {
                "measure": "time to maximum plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }, 
            {
                "measure": "area under the plasma concentration curve from time of first dose to infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }, 
            {
                "measure": "apparent clearance (Cl/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }, 
            {
                "measure": "volume of distribution", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }, 
            {
                "measure": "elimination half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884935"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "the average and minimum saturation values of \u03b14 integrin over the dosing interval", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }, 
            {
                "measure": "incidence of serious adverse events (SAEs), infusion and hypersensitivity reactions, and other AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 16"
            }, 
            {
                "measure": "the presence of anti-natalizumab antibodies", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 16"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}